Literature DB >> 10632996

Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA.

M Niedrig1, M Lademann, P Emmerich, M Lafrenz.   

Abstract

We analysed serum samples of 209 subjects immunized with yellow fever vaccine 17D by different assays: neutralization test, immunofluorescence assay, haemagglutination inhibition test and ELISA, for presence of 17D-specific antibodies. Serum samples were taken from a few weeks up to 35 years after vaccination. The neutralization test had the highest sensitivity. There was no correlation of results between the serological assays. Considering NT titres > 1:10 as indicating protection, we found that about 75% of subjects remained immune even 10 years after vaccination, with a median NT titre of 1:40 in reactive sera.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10632996     DOI: 10.1046/j.1365-3156.1999.00496.x

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  43 in total

1.  Yellow Fever Immunizations: Indications and Risks.

Authors:  Mary E. Wilson; Lin H. Chen; Elizabeth D. Barnett
Journal:  Curr Infect Dis Rep       Date:  2004-02       Impact factor: 3.725

2.  Immune activation alters cellular and humoral responses to yellow fever 17D vaccine.

Authors:  Enoch Muyanja; Aloysius Ssemaganda; Pearline Ngauv; Rafael Cubas; Helene Perrin; Divya Srinivasan; Glenda Canderan; Benton Lawson; Jakub Kopycinski; Amanda S Graham; Dawne K Rowe; Michaela J Smith; Sharon Isern; Scott Michael; Guido Silvestri; Thomas H Vanderford; Erika Castro; Giuseppe Pantaleo; Joel Singer; Jill Gillmour; Noah Kiwanuka; Annet Nanvubya; Claudia Schmidt; Josephine Birungi; Josephine Cox; Elias K Haddad; Pontiano Kaleebu; Patricia Fast; Rafick-Pierre Sekaly; Lydie Trautmann; Denis Gaucher
Journal:  J Clin Invest       Date:  2014-06-09       Impact factor: 14.808

Review 3.  Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine.

Authors:  Huabin Liang; Min Lee; Xia Jin
Journal:  Cell Mol Immunol       Date:  2015-10-05       Impact factor: 11.530

4.  Plant-Produced Subunit Vaccine Candidates against Yellow Fever Induce Virus Neutralizing Antibodies and Confer Protection against Viral Challenge in Animal Models.

Authors:  Stephen Tottey; Yoko Shoji; R Mark Jones; Jessica A Chichester; Brian J Green; Konstantin Musiychuk; Huaxin Si; Slobodanka D Manceva; Amy Rhee; Moneim Shamloul; Joey Norikane; Rosane C Guimarães; Elena Caride; Andrea N M R Silva; Marisol Simões; Patricia C C Neves; Renato Marchevsky; Marcos S Freire; Stephen J Streatfield; Vidadi Yusibov
Journal:  Am J Trop Med Hyg       Date:  2017-11-30       Impact factor: 2.345

Review 5.  Efficacy and duration of immunity after yellow fever vaccination: systematic review on the need for a booster every 10 years.

Authors:  Eduardo Gotuzzo; Sergio Yactayo; Erika Córdova
Journal:  Am J Trop Med Hyg       Date:  2013-09       Impact factor: 2.345

6.  Yellow fever vaccination elicits broad functional CD4+ T cell responses that recognize structural and nonstructural proteins.

Authors:  Eddie A James; Rebecca E LaFond; Theresa J Gates; Duy T Mai; Uma Malhotra; William W Kwok
Journal:  J Virol       Date:  2013-09-18       Impact factor: 5.103

7.  Human coronavirus NL63 open reading frame 3 encodes a virion-incorporated N-glycosylated membrane protein.

Authors:  Marcel A Müller; Lia van der Hoek; Daniel Voss; Oliver Bader; Dörte Lehmann; Axel R Schulz; Stephan Kallies; Tasnim Suliman; Burtram C Fielding; Christian Drosten; Matthias Niedrig
Journal:  Virol J       Date:  2010-01-15       Impact factor: 4.099

Review 8.  Current status and future prospects of yellow fever vaccines.

Authors:  Andrew S Beck; Alan D T Barrett
Journal:  Expert Rev Vaccines       Date:  2015-09-14       Impact factor: 5.217

9.  Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers.

Authors:  Nicole P Lindsey; Kalanthe A Horiuchi; Corey Fulton; Amanda J Panella; Olga I Kosoy; Jason O Velez; Elizabeth R Krow-Lucal; Marc Fischer; J Erin Staples
Journal:  J Travel Med       Date:  2018-01-01       Impact factor: 8.490

10.  Coronavirus antibodies in African bat species.

Authors:  Marcel A Müller; Janusz T Paweska; Patricia A Leman; Christian Drosten; Klaus Grywna; Alan Kemp; Leo Braack; Karen Sonnenberg; Matthias Niedrig; Robert Swanepoel
Journal:  Emerg Infect Dis       Date:  2007-09       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.